Evidence map›Paper›PMID 30612104›Full record

ArticleBMJ case reports2019

Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE.

Katherine Dutton, Sinisa Savic, Roger Owen, Edward Vital

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Katherine DuttonLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Sinisa SavicLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Roger OwenDepartment of Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Edward VitalLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Leeds Teaching Hospitals NHS Trust · GBChapel Allerton Hospital · GBNIHR Leeds Musculoskeletal Biomedical Research Unit · GB

Funding

Department of Health CS-2013-13-032Department of Health RTF/01/097Medical Research Council MR/M01665X/1MRF_ MRF-159-0003-ELP-VITAL
6 · The paper itself

Abstract

We report an interesting case of hepatitis C virus-negative type II cryoglobulinaemic vasculitis (CV) in a patient with a background history of systemic lupus erythematosus. The type II CV became less responsive to traditional treatments over time and culminated in an intensive care unit admission with critical multiorgan failure. A detailed flow cytometric evaluation of the bone marrow proved to be helpful in treatment. It demonstrated that bortezomib was a viable alternative treatment option for the type II CV. The patient received bortezomib and has made a full and durable recovery.

Indexed as

Administration, IntravenousAftercareAntineoplastic AgentsBone MarrowBortezomibCryoglobulinemiaFemaleFlow CytometryHepatitis CHumansLupus Erythematosus, SystemicMiddle AgedMultiple Organ FailureTreatment OutcomeVasculitisAntineoplastic AgentsBortezomibconnective tissue diseasesystemic lupus erythematosusvasculitis

Identifiers

PMID30612104
PMCPMC6326268
OpenAlexW2908028221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.